Anna Laurell
Overview
Explore the profile of Anna Laurell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holmsten K, Eknert J, Ofverholm E, Papantoniou D, Jawdat F, Verbiene I, et al.
Clin Genitourin Cancer
. 2023 Jun;
21(6):e438-e448.
PMID: 37308329
Background: Immune checkpoint inhibitors (ICIs) have been established as a routine treatment in patients with metastatic urothelial cancer (mUC). However, there has been no standard of care after progression on...
2.
Lindskog M, Laurell A, Kjellman A, Melichar B, Rey P, Zielinski H, et al.
Eur Urol Open Sci
. 2022 May;
40:38-45.
PMID: 35638086
Background: The prognosis of patients with synchronous metastatic renal cell carcinoma (mRCC) is poor. Whereas single-agent tyrosine kinase inhibition (TKI) is clearly insufficient, the effects can be enhanced by combinations...
3.
Lindberg A, Eskelund C, Albertsson-Lindblad A, Kolstad A, Laurell A, Raty R, et al.
Hematol Oncol
. 2021 Oct;
40(1):22-30.
PMID: 34713465
Mantle cell lymphoma (MCL) is a rare, often aggressive type of B-cell lymphoma with poor survival and no cure. Cancer and cancer treatment has a negative impact on health-related quality...
4.
Stenman M, Staehler M, Szabados B, Sandstrom P, Laurell A, Lindskog M, et al.
Acta Oncol
. 2018 Dec;
58(3):306-312.
PMID: 30507262
Background: Metastatic papillary renal cell carcinoma (mPRCC) is understudied. The disease is often aggressive and specific treatment options are lacking. Patients And Methods: mPRCC patients (n = 86) referred to...
5.
Eskelund C, Albertsson-Lindblad A, Kolstad A, Laurell A, Raty R, Pedersen L, et al.
Haematologica
. 2018 May;
103(11):e541-e543.
PMID: 29794145
No abstract available.
6.
Jerkeman M, Eskelund C, Hutchings M, Raty R, Wader K, Laurell A, et al.
Lancet Haematol
. 2018 Feb;
5(3):e109-e116.
PMID: 29396091
Background: Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of...
7.
Laurell A, Lonnemark M, Brekkan E, Magnusson A, Tolf A, Wallgren A, et al.
J Immunother Cancer
. 2017 Jun;
5:52.
PMID: 28642820
Background: Accumulating pre-clinical data indicate that the efficient induction of antigen-specific cytotoxic CD8+ T cells characterizing viral infections is caused by cross-priming where initially infected DCs produce an unique set...
8.
Kolstad A, Pedersen L, Eskelund C, Husby S, Gronbaek K, Jerkeman M, et al.
Biol Blood Marrow Transplant
. 2017 Jan;
23(3):428-435.
PMID: 28039078
The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and...
9.
Eskelund C, Kolstad A, Jerkeman M, Raty R, Laurell A, Eloranta S, et al.
Br J Haematol
. 2016 Jul;
175(3):410-418.
PMID: 27378674
In recent decades, the prognosis of Mantle Cell Lymphoma (MCL) has been significantly improved by intensified first-line regimens containing cytarabine, rituximab and consolidation with high-dose-therapy and autologous stem cell transplantation....
10.
Albertsson-Lindblad A, Kolstad A, Laurell A, Raty R, Gronbaek K, Sundberg J, et al.
Blood
. 2016 Jun;
128(14):1814-1820.
PMID: 27354719
For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy. In this multicenter, open-label phase 1/2 trial, we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine...